This study is being done to study how exenatide, an FDA-approved drug that lowers blood sugar in non-pregnant patients with type II diabetes, works in pregnant women. To do this, the investigators will study the drug's pharmacokinetics (what the body does to the drug; specifically, how quickly your body breaks down and excretes exenatide) and pharmacodynamics (what the drug does to the body; specifically, how effectively exenatide helps the participants' pancreas secrete insulin and how well it controls blood sugar after a meal). There are only two main drug therapies (insulin injections and glyburide pills) currently used for gestational diabetes and not all women achieve good enough blood sugar control without side effects. Therefore, the investigators hope to find out if exenatide might also be helpful in gestational diabetes.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
13
10 microgram injected sub-cutaneously once
Magee Womens Hospital of UPMC
Pittsburgh, Pennsylvania, United States
RECRUITINGArea Under the Plasma Concentration Versus Time Curve (AUC) of glucose
Glucose concentration over the course of each study visit following mixed tolerance test
Time frame: Baseline and 1 week later
Area Under the Plasma Concentration Versus Time Curve (AUC) of exenatide
Drug concentration over the course of the second study visit
Time frame: 1 week after study enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.